|
|
Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically.
For next generation processes, Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of turning science into solutions on a daily basis.
With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany.
Number of employees : 6 203 people.
|
|
|
| 2018 | 2019 | Delta | | EUR (in Million) | % | EUR (in Million) | % | | Biopharmaceuticals | 1,212 | 100% | 1,441 | 100% | +18.84% |
|
|
|
| 2018 | 2019 | Delta | | EUR (in Million) | % | EUR (in Million) | % | | United States | 396.51 | 32.7% | 477.91 | 33.2% | +20.53% | | EMEA | 308.66 | 25.5% | 355.30 | 24.7% | +15.11% | | Asia Pacific | 124.56 | 10.3% | 164.30 | 11.4% | +31.91% | | Germany | 144.60 | 11.9% | 151.67 | 10.5% | +4.89% | | China | 83.90 | 6.9% | 106.82 | 7.4% | +27.31% | | South Korea | 72.82 | 6% | 82.68 | 5.7% | +13.53% | | France | 54.98 | 4.5% | 68.15 | 4.7% | +23.97% | | Americas | 26.12 | 2.2% | 33.74 | 2.3% | +29.2% |
|
|
|
| Vote  | Quantity | Free-Float | Company-owned shares | Total Float |
| Stock A |
1 |
92,180,190 |
23,690,281 |
25.7% |
0 |
0.0% |
25.7% |
|
|
|
| Name | Equities | % | | Sartorius Aktiengesellschaft | 68,450,400 |
74.3% | | Fidelity Management & Research Co. LLC | 1,115,712 |
1.21% | | Groupama Asset Management SA | 841,675 |
0.91% | | The Vanguard Group, Inc. | 728,947 |
0.79% | | Baillie Gifford & Co. | 662,688 |
0.72% | | Norges Bank Investment Management | 639,338 |
0.69% | | 1832 Asset Management LP | 500,883 |
0.54% | | Invesco Advisers, Inc. | 413,667 |
0.45% | | BlackRock Fund Advisors | 396,312 |
0.43% | | DNCA Finance SA | 341,385 |
0.37% |
|
|
|
|
- PEA / SRD eligible : YES / YES - - Compartiment A - CAC Next 20 / CAC All Shares, CAC All-Tradable, CAC Large 60, PEA, SBF 120, STOXX Europe 600, Stoxx France 50 |
|
|
|
|
| - Bloomberg Code : |
DIM:FP |
| - Reuters Code : |
STDM.PA |
| - Datastream Code : |
F:STED |
|
| Company contact information |
|
Sartorius Stedim Biotech Zone Industrielle les Paluds Avenue de Jouques BP 1051 FR-13781 Aubagne Cedex Phone : +33 (0)4 42 84 56 00 Fax : +33 (0)4 42 84 56 19 web site : http://www.sartorius-stedim.fr |
|
|
Sector Medical Equipment, Supplies & Distribution - NEC
Connections : Sartorius Stedim Biotech |
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
